KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After O...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
Read articleWhat are you looking for?
Latest news
Crown Bioscience opens Singapore Laboratory and Establishes Local Commercial Partner
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs Targeting Cancer and Autoimmune Diseases
Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
Acquisition expands global service offering to include access and analysis of unique clinical biospecimens
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
Crown Bioscience Publishes New Study in PLOS ONE Highlighting the Use of Clinically Relevant 3D In Vitro PDX-Derived ...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
MBL Obtains Regulatory Approval for SARS-CoV-2 and Influenza Virus Antigen Test OTC Kit
This product detects the SARS-CoV-2 and Influenza virus antigen in nasal swab fluid by the immunochromatography method. MBL can sell this product at pharmacies, drugstores and pharmacy online sites.
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After O...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
Crown Bioscience opens Singapore Laboratory and Establishes Local Commercial Partner
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs Targeting Cancer and Autoimmune Diseases
Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
Acquisition expands global service offering to include access and analysis of unique clinical biospecimens
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
Crown Bioscience Publishes New Study in PLOS ONE Highlighting the Use of Clinically Relevant 3D In Vitro PDX-Derived ...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
Crown Bioscience opens Singapore Laboratory and Establishes Local Commercial Partner
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
Acquisition expands global service offering to include access and analysis of unique clinical biospecimens
Crown Bioscience Publishes New Study in PLOS ONE Highlighting the Use of Clinically Relevant 3D In Vitro PDX-Derived ...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
Crown Bioscience have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CR...
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevan...
The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.
Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After O...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
KBI Biopharma, Inc. Secures Swissmedic Regulatory Establishment License for State-of-the-Art Mammalian Cell Manufactu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
Tim Lowery Appointed Interim CEO of KBI and Selexis
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmun...
Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) tha...
KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After O...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
KBI Biopharma, Inc. Secures Swissmedic Regulatory Establishment License for State-of-the-Art Mammalian Cell Manufactu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
Tim Lowery Appointed Interim CEO of KBI and Selexis
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
KBI Biopharma and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief...
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.
KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
MBL Obtains Regulatory Approval for SARS-CoV-2 and Influenza Virus Antigen Test OTC Kit
This product detects the SARS-CoV-2 and Influenza virus antigen in nasal swab fluid by the immunochromatography method. MBL can sell this product at pharmacies, drugstores and pharmacy online sites.
MBL Launches an OTC Kit for SARS-CoV-2 Antigen Test
Medical & Biological Laboratories Co., Ltd. successfully acquired regulatory approval on November 11, 2022 for its SARS-CoV-2 antigen test OTC kit “GLINE-2019-nCoV Agキット（一般用).”
Crown Bioscience & MBL Launch Joint Venture to Serve Japanese Biopharmaceutical Community
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
MBL Launches a Kit for Simultaneous Detection of SARS-CoV-2 and Influenza Virus Antigens
This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.
MBL Obtained European Quality Management System Certificate (IVDR)
The certification ensures that the CE marked diagnostic products supplied by MBL adhere to standards of quality and safety that ensure the highest level of patients’ health protection
MEBGEN BRAF Kit Receives MHLW Approval as Companion Diagnostic for Use with Patients with Melanoma
MBL announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare for production ...
Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media...
Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...
JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Value Creation in the Mi...
JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.
JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.
JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.
JSR and Asahi Kasei Medical Enter Co-promotion Agreement
JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated sales coll...
JSR Life Sciences Completes Integration of MBL into its Family of Companies
JSR Life Sciences that the JSR Corporation has finalized the acquisition of all outstanding shares in MBL. As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Sciences famil...
Upcoming events
BioProcess International Asia (Web Exhibition & Conference)
Webinar Exhibition & Conference - JapanCOPHEX 2023 (The 18th Korea Int’l Cosmetic·Pharmaceutical·Bio Process & Technology Exhibition)
KINTEX 1 (Korea International Exhibition Center 1), KoreaNews topics
JSR Life Sciences
JSR Life Sciences is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop & deliver products to treat disease & improve quality of life
Crown Bioscience
Crown Bioscience is a global CRO providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases
Selexis
Selexis is the global leader in mammalian cell line development that leverages best-in-class protein expression technologies & modular workflows to create highly specialized solutions
KBI Biopharma
KBI Biopharma is an award winning CDMO providing fully-integrated, accelerated drug development & biomanufacturing services to pharmaceutical & biotechnology companies globally
MBL
MBL is committed to being a leading manufacturer & supplier of diagnostic reagents that facilitate further advances in personalized medicine & individualization of medical care
JSR Corporation
JSR Corporation's mission is to contribute to social good by supplying materials to serve future generations & providing new value today for their customers & society